Statements (76)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
chemical compound
|
| gptkbp:affiliatedWith |
gptkb:ABC_Research_Center
|
| gptkbp:application |
treatment of Alzheimer's disease
|
| gptkbp:built |
facing regulatory hurdles
requires extensive testing |
| gptkbp:campusFacilities |
gptkb:XYZ_University
|
| gptkbp:chemicalFormula |
handle with care
stable under normal conditions requires specialized equipment amide stable for long-term storage requires specific reagents classified as a novel compound contains imidazole ring exhibits unique characteristics interacts with other compounds ongoing in laboratories potential in drug formulation reacts with specific substrates several derivatives synthesized studied for synergistic effects various formulations tested C12H15N3O2 |
| gptkbp:clinicalTrials |
ongoing
potentially significant |
| gptkbp:collaborates_with |
international research teams
|
| gptkbp:collaborations |
with government agencies
with academic institutions with pharmaceutical companies with biotech firms |
| gptkbp:compatibleWith |
exhibits anti-inflammatory properties
|
| gptkbp:composedOf |
via acylation reaction
|
| gptkbp:dissolved |
soluble in DMSO
|
| gptkbp:exhibits |
presented at conferences
|
| gptkbp:funding |
various grants received
funded_by_NIH |
| gptkbp:future_plans |
to establish efficacy
|
| https://www.w3.org/2000/01/rdf-schema#label |
WPC-1132
|
| gptkbp:impact |
mild nausea
|
| gptkbp:is_aimed_at |
neurodegenerative diseases
|
| gptkbp:isATypeOf |
123456-78-9
|
| gptkbp:judgingCriteria |
HPLC_and_NMR
|
| gptkbp:market |
not available commercially
|
| gptkbp:notableWork |
may influence future drug development
potential to advance treatment options |
| gptkbp:operational_status |
under investigation
|
| gptkbp:origin |
N-(4-(dimethylamino)phenyl)-2-(1H-imidazol-1-yl)acetamide
|
| gptkbp:patentCitation |
protected under international law
|
| gptkbp:patentNumber |
US9876543B2
|
| gptkbp:patentStatus |
patented
|
| gptkbp:publications |
multiple peer-reviewed articles
complies with ethical standards |
| gptkbp:regulatoryCompliance |
not_yet_approved_by_FDA
|
| gptkbp:related_to |
similar to WPC-1120
|
| gptkbp:releaseYear |
2020
|
| gptkbp:research |
published in scientific journals
actively engaged in studies. gaining interest utilizes various techniques |
| gptkbp:research_focus |
preclinical
to explore therapeutic potential |
| gptkbp:researchAndDevelopment |
promising results observed
|
| gptkbp:reviews |
subject to peer review
|
| gptkbp:route |
oral
|
| gptkbp:safety_features |
available upon request
requires further study |
| gptkbp:safetyFeatures |
completed
follow standard laboratory protocols |
| gptkbp:storage |
store in a cool, dry place
|
| gptkbp:target_audience |
research scientists
|
| gptkbp:targets |
specific receptors in the brain
|
| gptkbp:technology |
planned for 2024
contributes to scientific knowledge |
| gptkbp:triggerType |
inhibits specific enzymes
|
| gptkbp:uses |
research in pharmacology
|
| gptkbp:weight |
233.27 g/mol
|